Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 TUG1 antisense oligonucleotide trial in recurrent glioblastoma (TUG trial)
jRCT2041230136Phase 1Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TUG1 ASO in glioblastoma (GBM), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety and tolerability. Started Feb 2024; status: active, not recruiting.
02
Drugs
TUG1 ASO
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCT2041230136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230136.